Gynecologic Cancer
Specialty Channel

Featured Article
A Swedish study found that women who received the quadrivalent HPV vaccine were less likely to contract invasive cervical cancer than those who had not.
According to the ARIEL3 study, _______ extended PFS for ovarian cancer despite toxicities?
Evaluating women for postmenopausal bleeding aids in the early detection of, and implementation of prevention strategies for, endometrial cancer.
Focusing on patient-centered outcomes from the ARIEL3 trial, rucaparib extended PFS in the maintenance setting for ovarian cancer despite toxicities.
True or False: Pembrolizumab provided a durable clinical response in cisplatin-ineligible patients with advanced urothelial carcinoma and is associated with prolonged OS.
Tumor-specific TP53 variants were detected in Papanicolaou tests for routine cervical cancer screenings up to 6 years before ovarian cancer diagnosis.
Researchers have found that EAOC often occurs within 36 months of follow-up for endometrial cysts, suggesting that cancer cells are in endometrial cysts.
For patients undergoing surgery for gynecologic cancer, oral apixaban is easier and less painful to administer than subcutaneous enoxaparin.
Molecular classification has strong prognostic value in high-risk endometrial cancer and should be incorporated in future trials to target subgroups of patients.

News

A Swedish study found that women who received the quadrivalent HPV vaccine were less likely to contract invasive cervical cancer than those who had not.
Evaluating women for postmenopausal bleeding aids in the early detection of, and implementation of prevention strategies for, endometrial cancer.
Focusing on patient-centered outcomes from the ARIEL3 trial, rucaparib extended PFS in the maintenance setting for ovarian cancer despite toxicities.
Tumor-specific TP53 variants were detected in Papanicolaou tests for routine cervical cancer screenings up to 6 years before ovarian cancer diagnosis.

Interactive Features

According to the ARIEL3 study, _______ extended PFS for ovarian cancer despite toxicities?
True or False: Pembrolizumab provided a durable clinical response in cisplatin-ineligible patients with advanced urothelial carcinoma and is associated with prolonged OS.
True or false: Maintenance olaparib did not provide a significant OS improvement in a phase 3 study of patients with platinum-sensitive, BRCA-mutated, relapsed ovarian cancer.
True or false: Maintenance pazopanib improved overall survival in advanced ovarian cancer in a phase 3 clinical trial.
Stay in the know.
OncNet Newsletter